... play an important role in cancer therapy to detect or to deliver the drug to the cancerous cell without attacking the normal cells and have good ability to form a complex with a variety of drugs ... nanomedicine for can-cer therapy. Prog Polym Sci. 2008; 33: 113-137. 6. Sumer B, Gao J. Therapeutic nanomedicine for cancer. Nano- medicine 2008; 3: 137-140. 7. Kabanov AV, Gendelman HE. Nanomedicine ... vitro cytotoxicity of SLNs carrying anticancer drugs was higher than that of conventional drug formulations [22]. 5-FU is an anticancer agent and the most widely used drug in the treatment...
... it to the lysosome. Once mutatedGC is localized to the lysosome, the glucosylceramidesubstrate is able to displace the inhibitor and allowthe enzyme to turn over glucosylceramide, owing to Fig. ... the ER, and by binding to the folded mutantGC enzyme population in the ER, shift the equilibriumtowards folding allowing mutant GC to be trafficked to the Golgi and on to the lysosome more efficiently,where ... receptor, endocytosed and delivered to the lyso-some, where it partially restores GC activity. In spiteof the fact that lysosomal localization is very ineffi-cient, ERT is currently the treatment...
... (1624 – 1689) to clarify in words, early organic chemists to purify and put into bottles, and the pharmaceutical industry of today to redesign, synthesize, and put into pills. Today, molecular ... for medicine. Computers are a kind of sharper stone tool, and the drugs they help design are a modern purifi ed and refi ned form of the herb. Today, as in the evolution from stone blade to electronics, ... electronics, few of the latest tools have failed to be pressed somehow into the service of agriculture and medicine. In the recent past we have seen new tools necessitate other tools. X - ray machines,...
... range of surgery in the treatment of spine meta-static tumours. Ortop Traumatol Rehabil 2003, 5(2):172-9.13. Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S: Risk factorsand probability of ... evidence of disease90 Able to carry on normal activity, minor signs and symptoms80 Normal activities with effort, some signs or symptoms70 Care for self, unable to carry on normal activity ... related to many factors suchas the general condition of the patient, their ability to carry on normal activity and care for them self, and thedegree of their disability. Other important factors...
... exposed to indomethacin prior to delivery [27,28]. These complications are thought to berelated to the extent to which the individual NSAID selectivelyinhibits cyclooxygenase (COX)1 as opposed to ... rheumatologists. Of 463 pregnancies identified byrheumatologists, detailed data were gathered on 95pregnancies, 84 of which were determined to have beenexposed to a tumor necrosis factor inhibitor. ... chlorpromazine studied by whole body autoradiography.Acta Pharmacol Toxicol 1972, 31(suppl 2):1-31.64. Hart CW, Nauton RF: The ototoxicity of chloroquine phos-phate. Arch Otolaryngol 1964, 80:407-412.65....
... or neuropathic pain to allow acomparison to be made.Other workers have attempted to calculate numbers needed to treat for osteoarthritis trials. For example, NNTs of 3 to 4were calculated ... 4.2 (95%CI 3.8 to 8.6) and 2.6 (2.0 to 3.9) for 30 and 60 mg etoricoxibin osteoarthritis compare well with those found for at least50% pain relief in postoperative pain (range 2 to more than ... than 6[22]), migraine (2.6 to 5.4 [21]), and neuropathic pain (2.6 to more than 8 [23]). For a 50% improvement in symptomsaccording to the American College of Rheumatology criteria(ACR50) after...
... injectingthe drug treated cells, mice from all groups were sacri-ficed with CO2inhalation. Sterile PBS (10 ml) wasinjected into the peritoneum of each mouse to obtainperitoneal cells. Peritoneal cells ... theintraperitoneal cavity by peritoneal wash (PW) and analyzed usingflow cytometry specific for GFP and doxorubicin. Representativefigures from the flow cytometry data showing migration ofperitoneal ... doxorubicin is auto-fluoresence, after 2 hours of incubation with the drug,the doxorubicin-treated MOSEC cells were subjected to flow cytometry analysis. As shown in Figure 1A, histo-grams of...
... transfer totreat flail shoulder after brachial plexus palsyRicardo Monreal*, Luis Paredes, Humberto Diaz and Pastor LeonAddress: Manuel Fajardo Teaching Hospital. Orthopedics and Traumatology ... transfershave been advocated to restore movement and stability of the shoulder. Paralysis of the deltoidand supraspinatus muscles can be treated by transfer of the trapezius.Methods: We treated 10 patients, ... deep to superficial through the trapezius.The partly detached deltoid is split longitudinally to expose the proximal humerus, which is scored with anosteotome. The arm is then abducted to 90°,...
... hyperreflexia-a mild Guillain-Barre Syndrome variant, totreat or not to treat? Nitin K Sethi*1, Josh Torgovnick1, Edward Arsura2, Alissa Johnston3 and Elizabeth Buescher3Address: 1Department ... advisable to be certain that the disease does not progress or relapse.ConclusionIt is not our intention by highlighting this case to discussthe physiology behind brisk reflexes in GBS but rather to raise ... would have been any differenthad treatment been withheld. In their article Green et.almention that treatment may be unnecessary in patientswho remain ambulatory during the second week of illness[5]....
... theradial head, it is mandatory to stabilize the radial headby a transcapitel lar K wire to prevent redislocation [4,7].In one study, Hori et al. reported that of the 13 patientstreated surgically ... the radial head. The optimum treat- ment in these patients is lengthening of the osteotomyin addition to angulation. The e xcellent results of alengthening osteotomy are best reflected in the ... incision 15 mmlong, a low-energy corticotomy of the ulna was per-formed at the proposed site (Figure 5). We did notmake any attempt to hyperangulate the ostotomy intrao-peratively. Distraction...
... remains to be seen whether tumor necrosis factor(TNF) blockade with biological agents will have a role to play in the management of type 2 reactions.We are currently expanding our treatment protocol ... damage in leprosy patients leads to deformities and disabilities. Oralcorticosteroids are given early to prevent permanent injury. We present a new approach to treat well-established nerve damage ... disease andearly treatment will prevent further disabilities [1,2].Mycobacterium leprae have an affinity for peripheral nerves.The nerve damage affects sensory, motor, and autonomicfibers....
... Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, ... http://arthritis-research.com/content/12/1/109doi:10.1186/ar2924Cite this article as: Firestein GS: ‘Rac’-ing upstream totreat rheumatoid arthritis. Arthritis Research & Therapy 2010, 12:109.Page 2 of 2 ... histology suggests that the Rac1 inhibitory peptide might be acting through vascular leakage and tissue edema rather than immune cell infi ltration into the joint.A second important point is...
... responses to treatment according to patient globalself-assessment and physician global assessment com-pared with patients treated with triamcinolone acetonide(Figure 4).Inflammatory markersAt ... wherever possible, treatment was adminis-tered by an unblinded pharmacist, nurse or physicianwhowasnotinvolvedinanyofthestudyassessments,allowing the investigator tobeblindedtotreatment.This ... informed of their assigned treatment duringthe study; physicians were not blinded to treatment.PatientsKey inclusion criteria were: patients aged 18 to 80 yearswith a history of at least one previous...